Skip to main content Skip to Footer


March 20, 2014
How are life sciences companies responding to healthcare reform? (6 of 6)
By: Anne O'Riordan

The life sciences industry faces a new set of issues potentially affecting existing business models, in the form of major ongoing changes to healthcare systems in North America and Europe.

In Accenture’s 2013 Global Risk Management Study, Daniel Imhof, risk director of Hoffman-La Roche, said “People realize now that if we had moved more effectively in anticipation of [healthcare reform], we would be better prepared to face today’s challenges.” The good news, however, is that as many as 67 percent of survey respondents have created a centralized program team to address changes required by healthcare reform.

Figure 4.0: How are Life Sciences Companies Responding

I hope you enjoyed this series examining some of the most notable findings from our latest risk study. To read all the findings from our study:

More blogs on this topic